Lead Product(s) : Thiotepa
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 24, 2020
Lead Product(s) : Thiotepa
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable